Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
Harvard Business School
Medtronic
Dow

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 5,290,540

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 5,290,540
Title: Method for treating infectious respiratory diseases
Abstract:A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.
Inventor(s): Prince; Gregory A. (Potomac, MD), Hemming; Val G. (Gaithersburg, MD)
Assignee: Henry M. Jackson Foundation for the Advancement of Military Medicine (Rockville, MD)
Application Number:07/877,095
Patent Claims:see list of patent claims

Details for Patent 5,290,540

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Csl Behring Ag CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN immune globulin intravenous (human) For Injection 102367 2000-07-27 ⤷  Try it Free 2011-05-01
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 2004-06-04 ⤷  Try it Free 2011-05-01
Schering Corporation A Subsidiary Of Merck & Co., Inc. PEGINTRON/ REBETOL COMBO PACK peginterferon alfa-2b and ribavirin 125196 2008-06-13 ⤷  Try it Free 2011-05-01
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 2007-07-26 ⤷  Try it Free 2011-05-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Baxter
Moodys
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.